RecruitingNot applicableNCT06666634
Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
Studying Squamous cell carcinoma of the penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Netherlands Cancer Institute
- Intervention
- Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- NKI-AVL, Amsterdam, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06666634 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the penis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05526989Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE3NCT02305654International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)Institute of Cancer Research, United Kingdom